Medtech and wellness company electroCore Inc. (NASDAQ: ECOR) reported promising new data supporting its non-invasive vagus nerve stimulation (nVNS) therapy for patients with mild traumatic brain injury (mTBI). The findings were presented at the 2025 International Brain Injury Association World Congress.
The study, led by Dr. Michael Ament of Cherry Creek Neurology, examined 102 patients with mTBI using electroCore's gammaCore nVNS non-invasive stimulation device. The results showed significant symptom improvements in 22 out of 27 measured categories, including post-traumatic headache, nausea, dizziness, and depression. Notably, these improvements were seen regardless of how recent or chronic the injury was--some dating back more than three years.
Dr. Peter Staats, Chief Medical Officer of electroCore, commended Dr. Ament's research, stating, "Dr. Ament is to be applauded for his efforts in demonstrating the clinical efficacy of gammaCore in improving concussive symptoms in such a large patient cohort. His work highlights the importance of vagus nerve stimulation as a viable treatment option for patients suffering from the debilitating effects of mild TBI."
This reinforces the potential for gammaCore to serve as a treatment option for lingering symptoms from mild brain injuries, an area with few nonpharmaceutical solutions. The device delivers electrical stimulation to the vagus nerve through the skin and is already cleared for other indications, such as migraine and cluster headaches.
The post electroCores gammaCore Shows Promise in Treating Concussive Symptoms from Mild Brain Injuries appeared first on PRISM MarketView.
COMTEX_464651326/2927/2025-04-17T13:00:33
/Computer%20board%20micro%20chip%20green%20by%20blickpixel%20via%20Pixabay.jpg){kind=tracking}
